Study of HRS-5041 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Inclusion criteria

• Able and willing to provide a written informed consent.
• Age 18-80 years old, gender unlimited.
• The physical status score of the Eastern Tumor Cooperative Group (ECOG) was 0 ~ 1.
• Predicted survival ≥12 weeks.
• Histological or cytological confirmed adenocarcinoma of the prostate.
• Patients progressed on taxane chemotherapy and at least one prior secondary hormonal therapy.

Exclusion criteria

• Prior treatment with an androgen receptor (AR) degrader.
• Plan to receive any other antitumor therapy during this trial.
• Receiving other investigational drugs or treatments that are not on the market within 4 weeks prior to the initial administration of the study.
• Patients with known brain metastases.
• Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness.